MNG639
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.749
- INFLAMMATORY_RESPONSE+0.659
- ANGIOGENESIS+0.641
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.638
- IL6_JAK_STAT3_SIGNALING+0.629
- ALLOGRAFT_REJECTION+0.595
- KRAS_SIGNALING_UP+0.547
- INTERFERON_GAMMA_RESPONSE+0.525
- IL2_STAT5_SIGNALING+0.511
- ANDROGEN_RESPONSE+0.502
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.407
- DNA_REPAIR-0.403
- E2F_TARGETS-0.207
- PEROXISOME-0.197
- WNT_BETA_CATENIN_SIGNALING-0.171
- MITOTIC_SPINDLE-0.150
- NOTCH_SIGNALING-0.087
- BILE_ACID_METABOLISM-0.065
- FATTY_ACID_METABOLISM-0.058
- ADIPOGENESIS-0.038
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG918 | — | — | 0.971 |
| 2 | SRR10900576 | — | — | 0.925 |
| 3 | MNG281 | — | — | 0.924 |
| 4 | SRR1797276 | — | cohortMD2 | 0.924 |
| 5 | MNG120 | — | — | 0.914 |
| 6 | SRR1797300 | — | cohortMD2 | 0.914 |
| 7 | MDT-AP-2651 | Med | Medulloblastoma | 0.904 |
| 8 | s_150324_4b | EPN | Posterior Fossa EPN | 0.903 |
| 9 | MDT-AP-2910 | Med | Medulloblastoma | 0.903 |
| 10 | MNG553 | — | — | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.749 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.659 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.641 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.638 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.629 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.595 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.547 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.525 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.511 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.502 | Inavolisib | — uncovered |
| COAGULATION | 0.493 | Binimetinib | — uncovered |
| COMPLEMENT | 0.490 | Inavolisib | — uncovered |
| APOPTOSIS | 0.474 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.463 | Inavolisib | — uncovered |
| HYPOXIA | 0.442 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.419 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.368 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.326 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.319 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.313 | Inavolisib | — uncovered |